Patents by Inventor Richard K. Bestwick

Richard K. Bestwick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Exon skipping compositions for treating muscular dystrophy
    Patent number: 11932851
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Grant
    Filed: December 22, 2020
    Date of Patent: March 19, 2024
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Diane Elizabeth Frank
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20240042049
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Application
    Filed: October 28, 2022
    Publication date: February 8, 2024
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Frederick Joseph SCHNELL
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20230104708
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: May 11, 2022
    Publication date: April 6, 2023
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220364093
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: June 3, 2022
    Publication date: November 17, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • Exon skipping oligomer conjugates for muscular dystrophy
    Patent number: 11491238
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: November 8, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Frederick Joseph Schnell
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220259592
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: October 11, 2021
    Publication date: August 18, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • Processes for preparing oligomers
    Patent number: 11384105
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 12, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas, Diane Elizabeth Frank, Richard K. Bestwick
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20220056442
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: April 19, 2021
    Publication date: February 24, 2022
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK, Frederick Joseph SCHNELL
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20220017901
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 50 skipping are described. In various aspects, antisense oligomers are described according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein T, Nu, n, and R100 are defined herein.
    Type: Application
    Filed: June 11, 2021
    Publication date: January 20, 2022
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Frederick Joseph Schnell, Baozhong Cai, Ankur Desai, Richard K. Bestwick
  • PROCESSES FOR PREPARING OLIGOMERS
    Publication number: 20210198296
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to sealing up oligomer synthesis while maintaining overall yield and parity of a synthesized oligomer.
    Type: Application
    Filed: November 16, 2020
    Publication date: July 1, 2021
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Baozhong CAI, Mitchell MARTINI, Ross SHIMABUKU, Katie THOMAS, Diane Elizabeth FRANK, Richard K. BESTWICK
  • EXON SKIPPING OLIGOMERS FOR MUSCULAR DYSTROPHY
    Publication number: 20210187003
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 45 skipping are described.
    Type: Application
    Filed: July 28, 2020
    Publication date: June 24, 2021
    Inventors: Diane Elizabeth FRANK, Richard K. BESTWICK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20210180064
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Application
    Filed: December 22, 2020
    Publication date: June 17, 2021
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPHY
    Publication number: 20210138078
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Application
    Filed: July 24, 2020
    Publication date: May 13, 2021
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Frederick Joseph Schnell
  • Exon skipping compositions for treating muscular dystrophy
    Patent number: 10907154
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 44 skipping are described.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: February 2, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Diane Elizabeth Frank
  • Processes for preparing oligomers
    Patent number: 10875880
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: May 24, 2017
    Date of Patent: December 29, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas, Diane Elizabeth Frank, Richard K. Bestwick
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20200339985
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: December 4, 2019
    Publication date: October 29, 2020
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • Exon skipping oligomer conjugates for muscular dystrophy
    Patent number: 10758629
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 52 skipping are described.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: September 1, 2020
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Richard K. Bestwick, Frederick Joseph Schnell
  • EXON SKIPPING OLIGOMER CONJUGATES FOR MUSCULAR DYSTROPY
    Publication number: 20200190516
    Abstract: Antisense oligomers complementary to a selected target site in the human dystrophin gene to induce exon 50 skipping are described. In various aspects, antisense oligomers are described according to Formula (I): or a pharmaceutically acceptable salt thereof, wherein T, Nu, n, and R100 are defined herein.
    Type: Application
    Filed: December 11, 2019
    Publication date: June 18, 2020
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Frederick Joseph SCHNELL, Baozhong CAI, Ankur DESAI, Richard K. BESTWICK
  • EXON SKIPPING COMPOSITIONS FOR TREATING MUSCULAR DYSTROPHY
    Publication number: 20200040336
    Abstract: Antisense molecules capable of binding to a selected target site in the human dystrophin gene to induce exon 53 skipping are described.
    Type: Application
    Filed: March 19, 2019
    Publication date: February 6, 2020
    Applicant: Sarepta Therapeutics, Inc.
    Inventors: Richard K. BESTWICK, Diane Elizabeth FRANK
  • PROCESSES FOR PREPARING OLIGOMERS
    Publication number: 20200040020
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomersynthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Application
    Filed: May 24, 2017
    Publication date: February 6, 2020
    Inventors: Bao CAI, Mitchell MARTINI, Ross SHIMABUKU, Katie THOMAS, Diane Elizabeth FRANK, Richard K. BESTWICK